Jim Simons E Ffector Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.49 - $0.88 $417,794 - $750,324	-852,641 Reduced 96.79%	28,267 $17,000
Q2 2023 Aug 11, 2023	BUY	$0.35 - $1.39 $257,952 - $1.02 Million	737,008 Added 512.17%	880,908 $731,000
Q1 2023 May 12, 2023	SELL	$0.35 - $0.67 $26,600 - $50,920	-76,000 Reduced 34.56%	143,900 $51,000
Q4 2022 Feb 13, 2023	BUY	$0.38 - $0.66 $9,310 - $16,170	24,501 Added 12.54%	219,900 $94,000
Q3 2022 Nov 14, 2022	BUY	$0.08 - $1.41 $13,288 - $234,216	166,111 Added 567.16%	195,399 $112,000
Q2 2022 Aug 12, 2022	BUY	$1.3 - $3.84 $38,074 - $112,465	29,288 New	29,288 $42,000

6.46M

Ticker EFTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,452,800
Description
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-sma...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.